Menu
Back to Journals » OncoTargets and Therapy » Volume 15
Efficacy and Safety of Gefitinib Plus Pemetrexed/Platinum in Advanced EGFR-Mutated Lung Adenocarcinoma Patients: A Real-World Observational Study [Retraction]
Received 19 October 2022
Accepted for publication 19 October 2022
Published 21 October 2022 Volume 2022:15 Pages 1271—1272
Wang R, Wu Q. Onco Targets Ther. 2022;15:31–39.
At the authors request, the Editor and Publisher of OncoTargets and Therapy wish to retract the published article. The authors contacted the journal to advise that several actions reported in the article were not performed and some of the data had been falsified. Specifically, the retrospective collection and analysis of data from 30 advanced lung adenocarcinoma patients with EGFR mutations described in the Control Cohort section on page 32 did not occur.
The authors wish to apologise for their actions and the inconvenience this has caused.
We have been informed in our decision-making by our policy on publishing ethics and integrity and the COPE guidelines on retractions.
The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.
This retraction relates to this paper
© 2022 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.